Cosmetics or skin preparations

Abstract

To provide an agent providing a novel effect which can be used by being added to a cosmetic or an external preparation for skin.SOLUTION: There are provided a dermal matrix decomposition inhibitor, an MMP-2 activity inhibitor, and an MMP-14 activity inhibitor which contain one or more kinds selected from Rosa multiflora fruit extract and Panax ginseng extract.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to a cosmetic preparation or an external skin preparation. [Background technology]

[0002] Matrix metalloproteinases (MMPs) exist in the body and are enzymes that break down extracellular matrix (ECM) such as collagen and elastic fibers. MMPs are proteolytic enzymes that require metal ions, and more than 25 types have been identified. MMP activity is strictly controlled by their respective expression levels, activation mechanisms, and molecular balance with MMP inhibitors (TIMPs, tissue inhibitors of metalloproteinases).

[0003] MMP-14 indirectly binds to MMP-2 via TIMP-2 and activates MMP-2. Activated MMP-2 is known to degrade various components constituting the dermal matrix, such as gelatin, collagen types IV, V, VII, and XI, and elastin. Several plant extracts are known that have the effect of suppressing the activity of MMP-14 and MMP-2 (Patent Documents 1 to 5).

[0004] On the other hand, Rosa multiflora is the fruit of the Rosaceae family or a related plant, and it has been proposed to use an extract of Rosa multiflora as an active ingredient in an elastase inhibitor (Patent Document 6).

[0005] In addition, the roots of carrots (also called ginseng, scientific name: Panax ginseng) are used as raw materials for herbal medicines and health foods, and it has been proposed to use ginseng extract as an active ingredient in elastin production promoters (Patent Document 7). Furthermore, compound K, a metabolite of Panax ginseng, has been shown to have effects such as restoring the expression level of type I collagen, suggesting that compound K has anti-aging and moisturizing effects and may be used in cosmetics to protect the skin from ultraviolet rays and increase the moisture content of the skin (Non-Patent Document 1). It has also been reported that ginsenosides derived from Korean red ginseng suppress the expression of MMP-13 in articular cartilage and prevent the decomposition of cartilage (Non-Patent Document 2). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2009-29708 A [Patent Document 2] JP 2013-177439 A [Patent Document 3] Special Publication No. 2010-235548, [Patent Document 4] JP 2009-29710 A [Patent Document 5] JP 2012-193121 A [Patent Document 6] JP 2000-119189 A [Patent Document 7] JP 2012-56933 A [Non-patent literature]

[0007] [Non-Patent Document 1] Eunji Kim et al., Journal of Ginseng Research 2018;42:218-224 [Non-Patent Document 2] Je Hyeong Lee et al., European Journal of Pharmacology 2014;724:145-151 Summary of the Invention [Problem to be solved by the invention]

[0008] There is a demand for the development of anti-aging cosmetics and topical anti-aging skin preparations. In order to achieve anti-aging, it would be desirable to have a component that can inhibit the decomposition of various dermal matrices. [Means for solving the problem]

[0009] The present inventors discovered that both an extract of Star Anemone and an extract of Carrot have the effect of suppressing the expression of MMP-14, and thus completed the present invention.

[0010] The present invention provides the following: [1] A dermal matrix decomposition inhibitor comprising one or more extracts selected from the group consisting of star anise extract and carrot extract. [2] An MMP-2 activity inhibitor containing one or more extracts selected from star anise extract and carrot extract. [3] An MMP-14 activity inhibitor containing one or more extracts selected from star anise extract and carrot extract. [4] The agent described in 3, wherein the inhibition of MMP-14 activity is achieved by inhibiting expression of the MMP-14 gene. [5] The agent described in any one of 1 to 4, for use in an amount of 0.3 to 1.5 μg / ml containing one or more selected from a star anise extract and a carrot extract. [6] A composition containing one or more extracts selected from a star anise extract and a carrot extract at 0.3 to 1.5 μg / ml. [7] A composition containing one or more extracts selected from a star anise extract and a carrot extract, the composition having a concentration of 0.3 to 1.5 μg / ml when used. [8] The composition described in 6 or 7, for any one selected from the group consisting of inhibition of dermal matrix degradation, inhibition of MMP-2 activity, inhibition of MMP-14 activity, and inhibition of MMP-14 gene expression. [9] The composition described in any one of items 6 to 8, which is a cosmetic or a topical skin preparation. Effect of the Invention

[0011] The present invention provides components and compositions that are expected to have anti-aging effects and the like. [Brief description of the drawings]

[0012] [Figure 1] 1 is a graph showing the expression level of the MMP-14 gene. The expression level of the MMP-14 gene was significantly decreased by the addition of the star anise extract and the carrot extract. * indicates a significant difference at p<0.05. [Diagram 2] 1 is a graph showing the expression level of the MMP-14 gene. Addition of star fruit extract did not show any inhibitory effect on the expression of the MMP-14 gene. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] [Active ingredients] The present invention relates to an agent and a composition containing, as an active ingredient, one or more extracts selected from a Radix oleracea extract and a Carrot extract.

[0014] Rosa multiflora is the fruit of Rosaceae or its related plants. The Rosa multiflora extract used in the present invention may be obtained by squeezing the fruit or by extracting it with a solvent. The raw fruit may be fresh or may be treated by drying, defatting, bleaching, fermentation, or the like.

[0015] Carrot (scientific name: Panax ginseng) is sometimes called ginseng. Its roots are well known as the raw material for the herbal medicine ginseng. In the present invention, the carrot extract may be from any part of the carrot, including flowers, leaves, stems, and roots, but is preferably an extract made from carrot roots. The carrot extract used in the present invention may be one obtained by squeezing, or may be one extracted using a solvent. The raw material may be raw, or may have been subjected to processing such as drying, defatting, bleaching, and fermentation.

[0016] The extract of A. japonica and the extract of Ginseng can be obtained under various extraction conditions. Examples of the extraction solvent include water, alcohols (e.g., lower alcohols such as methanol and ethanol, or polyhydric alcohols such as propylene glycol (propane-1,2-diol), 1,3-butylene glycol, and glycerin), ketones such as acetone, esters such as diethyl ether, dioxane, acetonitrile, and ethyl acetate, organic solvents such as xylene, benzene, and chloroform, animal oils, vegetable oils, and supercritical carbon dioxide. These solvents can be used alone, or two or more of them may be used in any combination. A preferred example of the extraction solvent is any one selected from the group consisting of water, alcohols, and mixed solvents thereof. In a particularly preferred embodiment, water or a mixed solvent of water and ethanol, propylene glycol, 1,3-butylene glycol, or glycerin is used as the extraction solvent. This is because the components having the desired effect can be sufficiently extracted. When a mixed solvent with water is used, the ratio can be appropriately set. In the present invention, when the concentration of an aqueous solvent is expressed in %, it is a value based on volume unless otherwise specified. For example, a 90% ethanol solution refers to 90 ml of ethanol mixed with water to make a total volume of 100 ml.

[0017] The ratio of raw material and solvent during extraction can be appropriately adjusted. Specifically, for example, the following method can be used. That is, the plant raw material or dried product is crushed into fine powder, and 1 to 100 times the amount of extraction solvent is added, and the mixture is left to stand at room temperature under normal pressure for about 1 hour to 2 weeks, or extracted at a temperature below the boiling point of the extraction solvent for about 10 minutes to 10 days, and then filtered. The filtrate obtained is concentrated, dried under reduced pressure, or freeze-dried, as necessary, to obtain a plant extract.

[0018] The extract obtained as described above can be used as it is, but if necessary, it may be subjected to purification treatment such as deodorization and decolorization within a range that does not impair the intended effect. Such purification treatment may be performed by any conventional means, for example, filtration or adsorption, decolorization, purification using an ion exchange resin or an activated carbon column. Furthermore, a purified product in the form of a solution, paste, gel, or powder can be obtained by freeze-drying or concentration treatment.

[0019] [Application] The present invention provides an MMP-14 activity inhibitor containing one or more selected from a star anise extract and a ginseng extract. In the present invention, when the activity of MMPs is inhibited, it includes various cases in which the activity of the MMP, which is an enzyme protein, is inhibited, unless otherwise specified, and is not limited to cases in which the activity is inhibited by a specific mechanism. Specifically, the inhibition of MMP activity includes the inhibition of the expression of the MMP gene and the inhibition of the activity of the MMP protein. The inhibition of the expression of the MMP gene includes the inhibition of the transcription of the MMP gene to mRNA and the inhibition of the translation of the MMP mRNA to protein.

[0020] In a preferred embodiment, the MMP-14 activity inhibitor of the present invention is an inhibitor of the expression of the MMP-14 gene.

[0021] Whether or not a certain component has an inhibitory effect on the expression of MMP-14 can be confirmed, for example, as follows. Human fibroblasts are cultured in normal medium and conditions, and the target component is added to the culture medium. After several hours to several days have passed since the addition, the cells are harvested and RNA is extracted from the cells. cDNA is reverse transcribed from the RNA, and real-time PCR is performed on the obtained cDNA to measure the amount of MMP-14 cDNA. As a control, the same measurement is performed on cells cultured without the addition of the component, and by comparing the two, it is determined whether the target component has an inhibitory effect on MMP-14m expression. Commercially available kits can be used to extract RNA from cells, synthesize cDNA, and perform PCR.

[0022] MMP-14 is classified into the membrane-bound matrix metalloprotease group and is known as an enzyme that degrades type I collagen, type II collagen, and type III collagen, which are the main components of the dermal matrix of the skin. Other known substrates of MMP-14 include proMMP-2, proMMP-13, ADAM9, gelatin, fibronectin, vitronectin, laminin-1, -2 / 4 and -5, fibrin / fibrinogen, α1PI, perlecan, CD44, ICAM-1, tTG, LRP1, syndecan-1, αv-integrin, C3b, EMMPRIN, ApoE, MICA, betaglycan, IL-8, SLP1, CTGF, DR6, DJ-1, galectin-1, Hsp90α, pentraxin 3, progranulin, Cyr61, peptidyl-prolyl cis-trans isomerase A, dickkopf-1, KiSS-1, and Dll1 (e.g., Yoshifumi Itoh et al., Matrix Biology, 2015;44-46:207-223).

[0023] In addition, the expression of MMP-14 is greatly increased by exposure to ultraviolet light, which is thought to be one of the major factors in the decrease or denaturation of collagen caused by ultraviolet light, and in the formation of wrinkles in the skin, etc. Therefore, it is thought that the MMP-14 activity inhibitor of the present invention can be used to treat skin aging such as wrinkle formation and loss of elasticity.

[0024] MMP-14 indirectly binds to MMP-2 via TIMP-2 and activates MMP-2. Activated MMP-2 is known to degrade various components constituting the dermal matrix, such as gelatin, collagen types IV, V, VII, and X, and elastin. Therefore, the MMP-14 activity inhibitor of the present invention can also be used as an MMP-2 activity inhibitor and an inhibitor of dermal matrix degradation. In addition, fibronectin and proteoglycan core protein are known as substrates for MMP-2 (see, for example, Robert E. Hewitt et al., Trends in Glycoscience and Glycotechnology, 1996;8(39):23-36).

[0025] Carrot extract has been known to promote elastin production (Patent Document 7, supra). However, elastin accounts for 2 to 5% of the dry weight of the dermis, whereas collagen, which is a substrate for MMP-14 or MMP-2, which is involved in the present invention, accounts for 70% of the dry weight. Therefore, the present invention, which relates to the inhibition of MMP-14 activity, can widely protect the dermal matrix, including collagen other than elastin, from degradation, and can treat wrinkles and loss of firmness and elasticity caused by ultraviolet rays and aging more effectively than before.

[0026] In addition, the decrease in type I collagen and type III collagen, which make up the majority of dermal fiber components, due to aging and ultraviolet rays is the main cause of decreased dermal density and loss of skin elasticity. Wrinkles caused by decreased elasticity tend to appear in areas that bend due to changes in facial expression, such as the corners of the eyes, around the mouth, and on the forehead, while decreased dermal density and elasticity cause fine wrinkles and unevenness over a wide area of ​​the entire skin, making the skin appear darker. In addition, a decrease in proteoglycan, a gel-like interstitial component that fills the spaces between collagen, elastin, and other fibers, leads to a loss of skin flexibility. Therefore, the present invention, which relates to the inhibition of MMP-14 activity, can protect type I and type III collagen and proteoglycan, which account for the majority of dermal fiber components, from degradation, and can maintain the firmness and flexibility of the skin. Furthermore, the present invention can treat fine wrinkles and irregularities that appear over a wide area due to a decrease in dermal density and loss of firmness, thereby improving the overall brightness of the skin.

[0027] Conventionally, the inhibitory effect of extracts of A. sieboldii on elastase activity has been known (Non-Patent Document 6, supra). However, there are several types of elastase, such as neutrophil elastase and fibroblast elastase, and the elastase known for extracts of A. sieboldii is derived from fibroblasts. It has been revealed that fibroblast-derived elastase activity is rather decreased in the elderly group of 60 years old and above, compared to the young group of about 15 to 38 years old (Skin 1987, 29, (5), P793-797 "Measurement of elastase-like enzyme activity derived from cultured human fibroblasts"). Therefore, it is considered that the effect of inhibiting fibroblast-derived elastase is limited on wrinkles and sagging skin, which become more serious after middle age. On the other hand, if the activity of MMP-14 can be suppressed, the activation of MMP-2, which increases with age, can be suppressed. Therefore, the present invention relating to the inhibition of MMP-14 activity can effectively treat age-related wrinkles, sagging skin, and loss of firmness and elasticity, which become more severe after middle age.

[0028] Furthermore, since collagen and laminin, which are substrates of MMP-14, are components of the basement membrane at the boundary between the epidermis and dermis, the present invention relating to the inhibition of MMP-14 activity is expected to inhibit the degradation of the basement membrane structure. Furthermore, since type VII collagen, which is a substrate of MMP-14, is called anchoring fibril and has the function of connecting the basement membrane structure and dermal collagen fibers, the inhibition of MMP-14 activity is expected to strengthen the connection between the dermis and epidermis by protecting the anchoring fibril. Furthermore, since MMP-14 is involved in the invasion of cancer cells and angiogenesis to the cornea, the present invention may also be useful in the development of pharmaceuticals for the treatment of cancer and corneal angiogenesis.

[0029] In the present invention, the term "treatment" includes actions other than medical procedures, and also includes preventing the onset of the target symptoms (also referred to as reducing the risk of onset or prevention) and suppressing the target symptoms (also referred to as anti-symptoms or treatment). Suppressing the target symptoms includes improving the target symptoms and suppressing their progression.

[0030] [Agents and compositions] The composition of the present invention is not particularly limited, but specific examples thereof include cosmetics, pharmaceuticals, beverages, foods, etc. The pharmaceuticals are not particularly limited, but specific examples thereof include skin external preparations, internal medicines, injections, etc. The agent of the present invention can be used as an ingredient of various compositions, specifically cosmetics or skin external preparations. The content of the active ingredient in the agent of the present invention or a composition containing the agent of the present invention (the total content of the extract of A. serrata and the extract of ginseng when the extract of A. serrata and the extract of ginseng are contained) is preferably 0.0000001 to 0.5% by mass (hereinafter simply indicated as "%)", more preferably 0.0001 to 0.3%, and even more preferably 0.0005 to 0.1% as solid content. From the viewpoint of more fully exerting the intended effect, it is preferably 0.03 to 5 μg / ml, more preferably 0.3 to 1.5 μg / ml, and even more preferably 0.3 to 0.7 μg / ml of the extract of A. serrata and 1.3 to 1.5 μg / ml of the extract of ginseng. Within this range, the active ingredient can be stably blended and can exert a high effect.

[0031] The cosmetic or topical skin preparation to which the agent of the present invention has been added may contain a component that is acceptable for use in a cosmetic or topical skin preparation and has an effect on the skin, provided that the effect of the agent of the present invention is not impaired. Examples of such components include whitening agents, UV protection agents, antibacterial agents, anti-inflammatory agents, cell activators, active oxygen removers, moisturizers, and skin homeostasis maintaining components.

[0032] In addition to the agent of the present invention, various additives acceptable for use in cosmetics or topical skin preparations can be blended into the cosmetic or topical skin preparation within the scope of not impairing the effects of the present invention. Examples of such additives include water (purified water, hot spring water, deep sea water, etc.), surfactants (emulsifiers, suspending agents, stabilizers, etc.), antioxidants, preservatives, gelling agents, alcohols, film-forming agents, colorants, fragrances, deodorants, salts, pH adjusters, cooling agents, chelating agents, keratolytic agents, enzymes, vitamins, etc.

[0033] Cosmetics or skin external preparations can also be prepared into compositions in various dosage forms such as solids, semi-solids, and liquids depending on the purpose of use. More specifically, the cosmetics of the present invention can be skin care cosmetics such as cleansers, face washes, lotions, milky lotions, creams, massage products, pack products, serums and gels, lip care products, etc.; base makeup cosmetics such as foundations, face powders, makeup bases, and concealers; point makeup cosmetics such as lipsticks, lip glosses and liners, cheek products, eye shadows, eyeliners, mascaras, eyebrow products, etc.; body care cosmetics such as soaps, liquid cleansers, sunscreen creams, and bath additives; and hair care cosmetics such as shampoos, rinses, hair treatments, hair styling products, hair tonics, hair growth agents, and scalp treatments. More specifically, the topical skin preparation of the present invention can be a plaster, an ointment, a cataplasm, a liniment, a lotion, an application agent, a patch, an aerosol (spray medicine), a microneedle array, or an iontophoresis agent.

[0034] The cosmetic or topical skin preparation may also be a packaged product. In these embodiments, in addition to the cosmetic or topical skin preparation, a packaged product may include a package (e.g., a box, container, label, instruction manual, tag) on ​​which the method of use and the intended effects and efficacy as described above are described. EXAMPLES

[0035] [Production Example 1: Production of Star Anemone Extract] 1000g of 50vol% 1,3-butylene glycol aqueous solution was added to 100g of dried fruit of Rosa multiflora Thunberg. This was extracted and filtered to obtain a rose extract. The dry solid content was 0.6%.

[0036] [Production Example 2: Production of carrot extract] 100 kg of ginseng roots were crushed, and 1000 L of 90 vol% ethanol solution was added to the crushed roots. Extraction was carried out at room temperature for 5 days, and then the extract was filtered to remove lees and precipitates. The ethanol content of the extract was adjusted to 50%, and a carrot extract was obtained. The dry solid content was 2.8%.

[0037] [Production Example 3: Production of star fruit extract] Approximately 100 L of 80 vol% ethanol was added to 10 kg of finely chopped Averrhoa carambola L. leaves, and the mixture was filtered. The resulting components were dissolved in 30% 1,3-butylene glycol solution to obtain a star fruit extract with a dry solid content of 1%.

[0038] [Production Example 4: Production of Star Anemone Extract] The radish was cut into small pieces, 50g of which was added to 500ml of water and left to soak at room temperature for 2 days. It was then filtered to obtain the radish extract. When the radish extract was concentrated, its dry solid content was 2.28%.

[0039] [Production Example 5: Production of carrot extract] Carrot leaves were cut into thin strips, and 50 g of the leaves were added to 500 ml of an aqueous solution (a homogeneous mixture of 250 ml of water and 250 ml of 1,3-butylene glycol) and soaked at room temperature for 3 days. The mixture was filtered to obtain a carrot extract. When the carrot extract was concentrated, its dry solid content was 2.35%.

[0040] . [Test example: MMP-14 expression inhibition test] Human fibroblasts (provided by RIKEN) were placed in a 6-well plate at 1.6x105 The cells were cultured at 37°C and 5% CO2.

[0041] Seeding was performed on day 1, and the extracts were added on day 2. The addition was performed so that the final concentration of the lyophilized product in the medium was 0.5 μg / ml for the Radix Atractylodes orthologus extract of Production Example 1, and 1.4 μg / ml for the Carrot extract of Production Example 2.

[0042] On the third day, the cells were harvested and RNA was extracted using the Rneasy Plus Mini Kit (Qiagen) according to the kit's protocol. The control was the addition of distilled water. The extracted RNA was stored at -80°C.

[0043] cDNA was synthesized from the extracted RNA using the iScrip Advanced cDNA Synthesis Kit for RT-qPCR (BioRAD) according to the kit's protocol. Real-time PCR was then performed using Sso Advanced SYBER GREEN Super Mix (BioRAD) according to the kit's protocol to measure the amount of MMP-14 cDNA.

[0044] The results are shown in Figure 1. The amount of MMP-14 cDNA was expressed as a relative value to the control. The addition of the Atractylodes arvensis extract and the carrot extract statistically significantly reduced the expression level of the MMP-14 gene. In other words, the addition of the Atractylodes arvensis extract and the carrot extract suppressed the expression of MMP-14.

[0045] [Comparative Example: Confirmation of the effect of star fruit in suppressing MMP-14 expression] As in the test example, the extract from star fruit (Averrhoa carambola L.) (Production Example 3) was used for the test. In Japanese Patent Application Laid-Open No. 2003-300893, it has been recognized that star fruit extract has a hyaluronic acid production promoting effect, an elastase inhibitory effect, and a collagenase inhibitory effect.

[0046] The results are shown in Figure 2. Star fruit extract did not show any inhibitory effect on MMP-14 expression.

[0047] [Prescription example] <Emulsion (oil-in-water type)> (Component) (%) 1. Polyoxyethylene monostearate (20E.O.) Sorbitan 1.0 2. Polyoxyethylene trioleate (20E.O.) Sorbitan 0.5 3. Glyceryl Monostearate 1.5 4. Stearic acid 0.5 5. Behenyl alcohol 0.5 6. Squalane 8.0 7. Carboxyvinyl polymer 0.1 8. Methyl parahydroxybenzoate 0.1 9. Sodium hydroxide 0.05 10. Remaining purified water 11. Star anise extract (Example 4) 0.03 12. Ethyl alcohol 5.0 13.Fragrance 0.05

[0048] (Manufacturing method) A: Mix ingredients 1 to 6 uniformly and dissolve at 70°C. B: Dissolve ingredients 7 to 10 uniformly and heat to 70°C. C: Add B to A and emulsify. D: After cooling to room temperature, add ingredients 11 to 13 and mix uniformly to obtain an emulsion.

[0049] <Ointment> (Component) (%) 1. Stearic acid 18.0 2. Cetanol 4.0 3. dl-α-tocopherol acetate 0.2 4. Triethanolamine 2.5 5. Glycerin 5.0 6. Dipotassium glycyrrhizinate 0.5 7. Carrot extract (Production Example 5) 5.0 8. Pentylene glycol 0.1 9. Remaining purified water

[0050] (Manufacturing method) A. Heat ingredients 1 to 3 together and maintain at 75°C. B. Mix ingredients 4 to 9 and keep at 75°C. Gradually add B to CA to obtain an ointment.

[0051] <Lotion> (Component) (%) 1. Polyoxyethylene monolaurate (20E.O.) Sorbitan 1.2 2. Ethyl alcohol 8.0 3. Ethyl parahydroxybenzoate 0.1 4. Glycerin 5.0 5.1,3-Butylene glycol 6.5 6. Para-butyryloxycinnamic acid 0.1 7. Star anise extract (Production Example 4) 0.03 8. Carrot extract (Production Example 2) 0.001 9. Remaining purified water

[0052] (Manufacturing method) A. Mix ingredients 1 to 3 and dissolve. B. Mix ingredients 4 to 9 and dissolve. CA and B are mixed uniformly to obtain a lotion.

[0053] <Liquid foundation (oil-in-water cream type)> (Component) (%) 1.1,3-Butylene glycol 5.0 2. Hydrogenated soybean phospholipids 0.5 3. Titanium dioxide 5.0 4. Bengala 0.1 5. Yellow iron oxide 1.0 6. Black iron oxide 0.05 7. Stearic acid 0.9 8. Glyceryl monostearate 0.3 9. Cetostearyl alcohol 0.4 10. Polyoxyethylene (20E.O.) Sorbitan Monooleate 0.2 11. Polyoxyethylene (20E.O.) Sorbitan Trioleate 0.2 12. Diethylamino hydroxybenzoyl hexyl benzoate 2.0 13. Acrylic acid / alkyl methacrylate copolymer (※4) 0.5 14. Triethanolamine 1.5 15. Glycerin 5.0 16. Phenoxyethanol 0.3 17. Remaining purified water 18. Atractylodes arbutus extract (Production Example 1) 1.0 19.Fragrance 0.02 *4 Pemulen TR-2 (manufactured by NOVEON)

[0054] (Manufacturing method) A: Disperse ingredients 1 to 6. B: Add ingredients 7 to 12 to A and mix uniformly at 70°C. C: Mix ingredients 13 to 17 uniformly at 70°C. D: Add B to C, emulsify and cool to room temperature. E: Add ingredients 18 and 19 to D and mix uniformly to obtain an oil-in-water creamy liquid foundation.

[0055] The various cosmetic compositions or topical skin preparations prepared above inhibit the activity of MMP-14, and are therefore expected to have an anti-aging effect by improving skin texture, firmness, and wrinkles when applied to the skin.

[0056] <Tablets> (Component) (%) 1.Lactose 24.0 2. Crystalline cellulose 20.0 3. Cornstarch 15.0 4. Carrot extract (Production Example 2) 0.5 5. Glycerol fatty acid ester 5.0 6. Silicon dioxide 1.0 7. Dextrin remaining amount

[0057] A. Mix ingredients 1 to 7 uniformly and obtain tablets according to a conventional method.

[0058] <Soft drinks> (Component) (%) 1. Fructose glucose liquid sugar 30.0 2. Emulsifier 0.5 3. Para-acetoxycinnamic acid 1.0 4. Star anise extract (Production Example 1) 0.1 5.Fragrance (appropriate amount) 6. Remaining purified water

[0059] A. Mix ingredients 1 to 6 uniformly and obtain a soft drink according to a conventional method.

[0060] These foods and beverages are expected to have MMP-14 activity suppression effects, anti-aging effects, etc.

Claims

1. An MMP-14 activity inhibitor containing Rosa multiflora extract, which is an extract of the fruit of Rosa multiflora, a plant of the Rosaceae family.

2. The agent described in claim 1, containing the star anise extract and the carrot extract.

3. The agent according to claim 1 or 2, wherein the inhibition of MMP-14 activity is achieved by suppressing expression of the MMP-14 gene.

4. The agent described in any one of claims 1 to 3, for use in an amount of 0.3 to 1.5 μg / ml of the Atractylodes chinense extract.

5. The agent according to any one of claims 1 to 4, for addition to a cosmetic or topical skin preparation.

6. The agent according to any one of claims 1 to 5, for improving wrinkles, loss of firmness and elasticity due to aging.

Images